Submitted by Anonymous (not verified) on 22 August 2024 - 9:46
Human medicines European public assessment report (EPAR): Tremelimumab AstraZeneca, tremelimumab, Date of authorisation: 20/02/2023, Revision: 1, Status: Withdrawn (authorisation)
Source: